Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.

Hakeda, Yoshiyuki, Kobayashi, Yukinao, Yamaguchi, Kyoji, Yasuda, Hisataka, Tsuda, Eisuke, Higashio, Kanji, Miyata, Takashi, Kumegawa, Masayoshi·1998·Biochemical and Biophysical Research Communications
DOI 10.1006/bbrc.1998.9523

Cited by (107)

Items 101–107 of 107

  1. Imunolocalização de CSF-1, OPG e RANKL no periodonto relacionado ao esmalte de incisivos de ratos em erupção normal e contida
    Juliana dos Santos Neves · 2008
  2. Rola RANK/RANKL i OPG w szpiczaku plazmocytowym* The role of RANK/RANKL and OPG in multiple myeloma
    Martyna Kandefer‐Szerszeń · 2006
  3. Elucidating Differences in Osteoclast Activation Mechanisms: Looking for Targets to Prevent Pathological Bone Resorption
    Diana P. Trebec‐Reynolds · 2010 · TSpace (University of Toronto)
  4. Translational Pharmacology in The Development of RANKL Inhibitors
    Brendan F. Boyce, Zhenqiang Yao · 2019 · Elsevier eBooks
  5. p57Kip2 is an essential regulator of vitamin D receptor-dependent mechanisms
    Katsuhiko Takahashi, Hitoshi Amano, Tomohiko Urano, Minqi Li, Meiko Oki, Kazuhiro Aoki, Norio Amizuka, Keiko Nakayama, Keiko Nakayama, Nobuyuki Udagawa et al. · 2023 · PLoS ONE
  6. Nouvelles approches thérapeutiques des ostéosarcomes.
    Yohann Wittrant · 2005
  7. Control of lymphoid organ CD169+ macrophage differentiation by stromal cells through the RANK-RANKL axis
    Abdouramane Camara · 2019 · theses.fr (ABES)